TW200718688A - Fluorinated ryridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls - Google Patents
Fluorinated ryridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroarylsInfo
- Publication number
- TW200718688A TW200718688A TW095113865A TW95113865A TW200718688A TW 200718688 A TW200718688 A TW 200718688A TW 095113865 A TW095113865 A TW 095113865A TW 95113865 A TW95113865 A TW 95113865A TW 200718688 A TW200718688 A TW 200718688A
- Authority
- TW
- Taiwan
- Prior art keywords
- oxidation
- nitrogen containing
- ryridine
- fluorinated
- oxide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67313105P | 2005-04-20 | 2005-04-20 | |
| US11/385,056 US7262210B2 (en) | 2005-04-20 | 2006-03-21 | Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200718688A true TW200718688A (en) | 2007-05-16 |
Family
ID=36685688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095113865A TW200718688A (en) | 2005-04-20 | 2006-04-19 | Fluorinated ryridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7262210B2 (enExample) |
| EP (1) | EP1879864A1 (enExample) |
| JP (1) | JP2008536918A (enExample) |
| KR (1) | KR20080004554A (enExample) |
| CN (1) | CN101228129A (enExample) |
| AU (1) | AU2006240423A1 (enExample) |
| BR (1) | BRPI0610506A2 (enExample) |
| CA (1) | CA2605480A1 (enExample) |
| MX (1) | MX2007013198A (enExample) |
| PE (1) | PE20061399A1 (enExample) |
| TW (1) | TW200718688A (enExample) |
| WO (1) | WO2006115652A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7829584B2 (en) * | 2006-03-21 | 2010-11-09 | Janssen Pharmaceutica Nv | Pyridines and pyridine N-oxides as modulators of thrombin |
| US7875636B2 (en) | 2006-04-12 | 2011-01-25 | Merck Sharp & Dohme Corp. | Pyridyl amide T-type calcium channel antagonists |
| KR20100072266A (ko) | 2007-10-24 | 2010-06-30 | 머크 샤프 앤드 돔 코포레이션 | 헤테로사이클 페닐 아미드 ｔ-형 칼슘 채널 길항제 |
| US9884822B2 (en) | 2012-02-09 | 2018-02-06 | Arch Chemicals, Inc. | Process for the preparation of 1-hydroxy-6-substituted pyridones |
| WO2015183709A1 (en) * | 2014-05-28 | 2015-12-03 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| CN105037280B (zh) * | 2015-06-23 | 2017-09-29 | 西安近代化学研究所 | 一种 2,6‑二氨基‑3,5‑二硝基吡嗪‑1‑氧化物的合成方法 |
| BR112018008506B8 (pt) * | 2015-10-29 | 2023-12-05 | Merck Sharp & Dohme | Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos |
| US10143681B2 (en) | 2016-08-22 | 2018-12-04 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| AU2018338194B2 (en) | 2017-09-22 | 2021-07-08 | Becton, Dickinson And Company | 4% trisodium citrate solution for use as a catheter lock solution |
| CN110818629A (zh) * | 2019-12-05 | 2020-02-21 | 杭州勇诚睿生物科技有限公司 | 一种合成氟代异烟酸衍生物的方法 |
| AU2022212785A1 (en) * | 2021-01-28 | 2023-07-27 | Merck Sharp & Dohme Llc | Factor xia inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4187379A (en) | 1978-11-13 | 1980-02-05 | Warner-Lambert Company | 3-Aryloxy-2-pyridinecarbonitrile 1-oxide compounds |
| DE3918834A1 (de) | 1989-01-26 | 1990-08-02 | Bayer Ag | Aryl- und heteroarylethanol-pyridylalkylamine, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer bei tieren und als mittel gegen adipositas |
| DK220890D0 (da) | 1990-09-14 | 1990-09-14 | Ole Buchardt | Fremgangsmaade til fremstilling af c-terminalt amiderede peptider |
| DE69210091T2 (de) | 1991-05-31 | 1996-10-02 | Sumitomo Pharma | Leukotrien-B4-Antagonisten |
| FR2686084B1 (fr) | 1992-01-10 | 1995-12-22 | Bioprojet Soc Civ | Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques. |
| DE59305738D1 (de) | 1992-11-29 | 1997-04-17 | Hoechst Ag | Verfahren zur Herstellung von halogenierten Benzoesäuren |
| TR199801255T2 (xx) | 1995-12-29 | 1998-10-21 | Smithkline Beecham Corporation | Vitronektin resept�r antagonistleri. |
| IL138245A0 (en) | 1998-03-10 | 2001-10-31 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| CA2430037A1 (en) | 2000-11-20 | 2002-05-30 | Michael S. South | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| US6610701B2 (en) | 2001-02-09 | 2003-08-26 | Merck & Co., Inc. | Thrombin inhibitors |
| US20030158218A1 (en) * | 2001-12-21 | 2003-08-21 | Nantermet Philippe G. | Thrombin inhibitors |
| US7550474B2 (en) | 2003-04-10 | 2009-06-23 | Johnson & Johnson Pharmaceuticals Research & Development, L.L.C. | Substituted phenyl acetamides and their use as protease inhibitors |
| WO2005010011A2 (en) | 2003-07-15 | 2005-02-03 | Xenoport, Inc. | Methods of synthesis of acyloxyalkyl compounds |
-
2006
- 2006-03-21 BR BRPI0610506-8A patent/BRPI0610506A2/pt not_active IP Right Cessation
- 2006-03-21 US US11/385,056 patent/US7262210B2/en not_active Expired - Fee Related
- 2006-03-21 JP JP2008507677A patent/JP2008536918A/ja not_active Withdrawn
- 2006-03-21 EP EP06739397A patent/EP1879864A1/en not_active Withdrawn
- 2006-03-21 AU AU2006240423A patent/AU2006240423A1/en not_active Abandoned
- 2006-03-21 MX MX2007013198A patent/MX2007013198A/es unknown
- 2006-03-21 CA CA002605480A patent/CA2605480A1/en not_active Abandoned
- 2006-03-21 CN CNA2006800219864A patent/CN101228129A/zh active Pending
- 2006-03-21 KR KR1020077025219A patent/KR20080004554A/ko not_active Withdrawn
- 2006-03-21 WO PCT/US2006/010581 patent/WO2006115652A1/en not_active Ceased
- 2006-04-18 PE PE2006000404A patent/PE20061399A1/es not_active Application Discontinuation
- 2006-04-19 TW TW095113865A patent/TW200718688A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20060241148A1 (en) | 2006-10-26 |
| AU2006240423A1 (en) | 2006-11-02 |
| MX2007013198A (es) | 2008-03-24 |
| KR20080004554A (ko) | 2008-01-09 |
| WO2006115652A1 (en) | 2006-11-02 |
| JP2008536918A (ja) | 2008-09-11 |
| CA2605480A1 (en) | 2006-11-02 |
| CN101228129A (zh) | 2008-07-23 |
| US7262210B2 (en) | 2007-08-28 |
| BRPI0610506A2 (pt) | 2010-06-29 |
| PE20061399A1 (es) | 2007-02-05 |
| EP1879864A1 (en) | 2008-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ598242A (en) | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer | |
| GEP20094679B (en) | Dipeptidyl peptidase inhibitors | |
| EA201890903A9 (ru) | Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе | |
| MX2009007050A (es) | Compuestos de carboxamida y su uso como inhibidores de calpaina. | |
| ATE432259T1 (de) | Pyridinderivate als dipeptedyl-peptidase-hemmer | |
| TW200718424A (en) | Novel compounds of amino sulfonyl derivatives | |
| WO2007109459A3 (en) | Pyridines and pyridine n-oxides as modulators of thrombin | |
| MXPA03011907A (es) | Fluoropirrolidinas como inhibidores de dipeptidil peptidasa. | |
| GEP20125537B (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| WO2003002530A3 (en) | Pyrrolidines as dipeptidyl peptidase inhibitors | |
| SG148177A1 (en) | Novel cis-imidazolines | |
| GEP20115171B (en) | Polymorphs of benzoate salt of 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor | |
| MX2009006864A (es) | Inhibidores novedosos de c jun-n-terminal cinasas. | |
| TWI348371B (enExample) | ||
| SG169983A1 (en) | Aspartic protease inhibitors | |
| MY162022A (en) | Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors | |
| MX2009013565A (es) | Derivados de azapeptidos. | |
| UA83875C2 (ru) | Производные хинолина для применения в качестве микобактериальных ингибиторов | |
| TN2009000109A1 (en) | New benzamide derivatives as brad ykinin antagonists | |
| IL173802A0 (en) | Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors | |
| MY150075A (en) | Novel phosphodiesterase inhibitors | |
| CY1111327T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος | |
| WO2009018065A3 (en) | Novel glucokinase activators and methods of using same | |
| MX2010008460A (es) | Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular. | |
| ATE432260T1 (de) | Pyridinderivate als pkc-theta-hemmer |